Age as a Predictor of Treatment Outcome in Metastatic Testicular Germ Cell Tumors
Age as a Predictor of Treatment Outcome in Metastatic Testicular Germ Cell Tumors
复制标题
DOI：
10.21873/anticanres.13753
复制
发表时间：
2019-10-01
影响因子：
2
通讯作者：
Gerger, Armin
中科院分区：
文献类型：
--
作者：
Terbuch, Angelika;Posch, Florian;Gerger, Armin
背景/目的：量化年龄对转移性睾丸生殖细胞肿瘤（TGCT）患者复发和死亡率的预后影响。患者和方法：回顾了1994年至2015年期间在单一学术中心接受治疗的1，225名TGCT患者的电子病历。结果：年龄越大，无进展生存期（PFS）越差或进展风险越高。相应的5年PFS估计值在40岁以下患者中为85%，在老年人群中为83%。尽管无统计学显著性，但年龄越大，总生存率（OS）越差（年龄每增加5年的单变量HR =1.18，95% CI=0.99-1.41）。这在回归分析中得到了解释，其中年龄预测治疗相关死亡的风险显著更高（p=0.022）。结论：老年转移性TGCT患者如果能够耐受风险适应性化疗，可以达到与年轻患者相似的高治愈率。
Background/Aim: To quantify the prognostic impact of age on relapse and mortality in patients with metastatic testicular germ cell tumors (TGCT). Patients and Methods: Electronical medical records of 1,225 TGCT patients who were treated at a single academic center between 1994 and 2015 were reviewed. Results: Higher age did not predict for worse progression-free survival (PFS) or for higher progression risk. The corresponding 5-year PFS estimates were 85% in patients younger than 40 years and 83% in the elderly population. Although not statistically significant, higher age was numerically associated with worse overall survival (OS) (univariate HR per five years increase in age=1.18, 95% CI=0.99-1.41). This was explained in regression analysis where age predicted for significantly higher risk of treatment-related death (p=0.022). Conclusion: Elderly patients with metastatic TGCT can achieve high cure rates similar to younger patients if they tolerate risk-adapted chemotherapy.